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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPEREffects of NO on Cell Proliferation 89
Claudio Napoli, Giuseppe Paolisso, Amelia Casamassimi, Mohammed Al-Omran, Michelangela Barbieri,
Linda Sommese, Teresa Infante, Louis J. Ignarro
Nitric oxide (NO) modulates cell proliferation, cell cycle arrest, and apoptosis. Napoli and
colleagues review the evidence that shows NO can either promote or inhibit cell proliferation.
Low relative concentrations of NO seem to favor cell proliferation and antiapoptotic
responses. Higher levels of NO favor pathways inducing cell cycle arrest, mitochondria
respiration, senescence, or apoptosis. The molecular mechanisms of NO inﬂuencing cell cycle
progression, include both cGMP-dependent and -independent pathways. Further
understanding of the effects of NO may lead to novel therapies against cardiovascular
diseases, especially in patients with diabetes.CLINICAL RESEARCH MINI-FOCUS: LEFT ATRIAL CLOSURE IN
ATRIAL FIBRILLATIONLow Rate of Embolic Strokes With Amplatzer LAAC in Patients With
Contraindications for Anticoagulation96Marina Urena, Josep Rodés-Cabau, Xavier Freixa, Jacqueline Saw, John G. Webb, Mélanie Freeman,
Eric Horlick, Mark Osten, Albert Chan, Jean-Francois Marquis, Jean Champagne, Réda Ibrahim
Urena and colleagues studied left atrial appendage closure (LAAC) with the Amplatzer
Cardiac Plug (ACP) in patients with nonvalvular atrial ﬁbrillation (NVAF) and absolute
contraindication for anticoagulation therapy. A total of 52 patients underwent LAACs. Most
patients received short-term (1 to 3 months) dual antiplatelet therapy after the procedure.
The procedure was successful in 98% of the patients. There was 1 device embolization
and 1 pericardial effusion, but no cases of periprocedural stroke. At a mean follow-up of
20 months, the rates of stroke, systemic embolism, and pericardial effusion were 1.9%, 0%,
and 1.9%, respectively. These results suggest that the ACP may safely reduce the risk of
stroke in patients with NVAF.(continued on page A-20)
JULY 9, 2013 (continued) A-20MINI-FOCUS: LEFT ATRIAL CLOSURE IN
ATRIAL FIBRILLATIONThoracoscopic Stand-Alone Left Atrial Appendectomy for
Thromboembolism Prevention in NVAF103Toshiya Ohtsuka, Mikio Ninomiya, Takahiro Nonaka, Motoyuki Hisagi, Takahiro Ota, Toru Mizutani
Ohtsuka and colleagues describe their experience with thoracoscopic stand-alone left atrial
appendectomy for thromboembolism prevention in patients with nonvalvular atrial
ﬁbrillation (NVAF). The left atrial appendage (LAA) was thoracoscopically excised with an
endoscopic cutter in 30 patients with previous thromboembolism. The mean operative time
was 32 min with no major complications, although 2 patients were converted to mini-
thoracotomy. After a mean follow-up of 16 months, there has been no recurrence of
thromboembolism despite discontinued anticoagulation. Thoracoscopic stand-alone
appendectomy is potentially safe and may allow surgeons to achieve relatively simple,
complete LAA closure.MINI-FOCUS: LEFT ATRIAL CLOSURE IN
ATRIAL FIBRILLATIONInitial Clinical Experience With Percutaneous LAA Suture Ligation
Using the LARIAT System108Krzysztof Bartus, Frederick T. Han, Jacek Bednarek, Jacek Myc, Boguslaw Kapelak, Jerzy Sadowski,
Jacek Lelakowski, Stanislaw Bartus, Steven J. Yakubov, Randall J. Lee
Bartus and colleagues report on the efﬁcacy and safety of left atrial appendage (LAA) closure
via a percutaneous ligation approach. The catheter-based LARIAT device consists of a snare
with a pre-tied suture that is guided epicardially over the LAA. A total of 81 of 85 patients
had complete LAA closure. There were no complications due to the device, but there were
3 access-related complications, including severe pericarditis, late pericardial effusion, and
unexplained sudden death. At 1-month and 3-months post-ligation, 95% of the patients had
complete LAA closure by transesophageal echocardiography. LAA closure with the
LARIAT device can be performed effectively with low rates of peri-procedural adverse
events.
Editorial Comment: Zoltan G. Turi, p. 119(continued on page A-21)
JULY 9, 2013 (continued) A-21CARDIOMETABOLIC RISKU-Shaped Relationship Between Hemoglobin A1C and
Risk of Cardiovascular Hospitalization121Gregory A. Nichols, Sandra Joshua-Gotlib, Shreekant Parasuraman
Nichols and colleagues evaluated the relationship between glycemic control, as measured by
glycated hemoglobin (A1C) levels, and cardiovascular disease (CVD) hospitalizations and
all-cause mortality. Data were collected from almost 30,000 members of an integrated health
plan. Compared with patients with mean A1C 7.0% to 7.4%, those with mean A1C <6.0%
had a 75% increased risk of CVD hospitalization, and the risk was signiﬁcantly higher for
those with A1C 6.0% to 6.4% and 6.5% to 6.9%. Patients with A1C 8.5% to 8.9% and >9.0%
also had increased risks. Similar results were found for all-cause mortality. The relationship
between mean A1C and CVD hospitalizations and all-cause mortality is U-shaped, with
greater risk at both higher and lower A1C levels.CARDIOMETABOLIC RISKBariatric Surgery Restores Healthy Small Vessel Anticontractile Activity 128
Reza Aghamohammadzadeh, Adam S. Greenstein, Rahul Yadav, Maria Jeziorska, Salam Hama,
Fardad Soltani, Phil W. Pemberton, Basil Ammori, Rayaz A. Malik, Handrean Soran,
Anthony M. Heagerty
In lean healthy humans, perivascular adipose tissue (PVAT) exerts an anticontractile effect on
adjacent small arteries, but this is lost in obesity-associated illnesses. Aghamohammadzadeh
and colleagues investigated the effects of bariatric surgery on PVAT. Segments of small
subcutaneous artery and perivascular fat were harvested before and 6 months after bariatric
surgery. The anticontractile activity of PVAT was absent before surgery in obese subjects
compared to lean controls and was restored 6 months after bariatric surgery. Superoxide
dismutase and catalase rescued PVAT anticontractile function in tissue from obese
individuals. Bariatric surgery normalizes PVAT anticontractile function via a reduction in
local inﬂammation and oxidative stress.
Editorial Comment: Sheldon E. Litwin, p. 136(continued on page A-24)
JULY 9, 2013 (continued) A-24HEART RHYTHM DISORDERSElimination of Stable Rotors or Focal Sources
May Underlie Successful AF Ablation138Sanjiv M. Narayan, David E. Krummen, Paul Clopton, Kalyanam Shivkumar, John M. Miller
Narayan and colleagues recently showed that speciﬁcally targeting areas of stable rotors and
focal sources can improve the efﬁcacy of atrial ﬁbrillation (AF) ablation procedures. For this
report, the long-term success of AF ablation was compared between patients whose
conventional AF ablation lines incidentally were directed at stable rotors and focal sources
compared to those who had these areas but they were not ablated. After analyzing lesion
placement on electroanatomic maps against AF source locations, AF sources were ablated
directly in 100% of targeted procedures and coincidentally in 45% of conventional cases.
After 1 procedure, AF was absent in 80% of patients if sources were ablated, but only 18% of
patients if sources were missed. Freedom from AF was highest if all sources were ablated,
intermediate if some sources were ablated, and lowest if no sources were ablated.
Editorial Comment: John D. Hummel, p. 148BIOMARKERSCopeptin May Be a Useful Biomarker for Chest Pain Patients 150
Alan Maisel, Christian Mueller, Sean-Xavier Neath, Robert H. Christenson, Nils G. Morgenthaler,
James McCord, Richard M. Nowak, Gary Vilke, Lori B. Daniels, Judd E. Hollander, Fred S. Apple,
Chad Cannon, John T. Nagurney, Donald Schreiber, Christopher deFilippi, Christopher Hogan,
Deborah B. Diercks, John C. Stein, Gary Headden, Alexander T. Limkakeng, Jr, Inder Anand,
Alan H.B. Wu, Jana Papassotiriou, Oliver Hartmann, Stefan Ebmeyer, Paul Clopton,
Allan S. Jaffe, W. Frank Peacock
Copeptin, the C-terminal portion of the arginine vasopresser precursor peptide, is secreted
from the pituitary rapidly following acute myocardial infarction (AMI). The CHOPIN trial
tested the hypothesis that copeptin <14 pmol/l and cardiac troponin I (cTnI) <99th
percentile in patients with a nondiagnostic electrocardiogram would effectively rule-out AMI
in patients presenting with chest pain. This was a 16-site study in nearly 2,000 patients
presenting within 6 h of the onset of chest pain. A negative copeptin and cTnI at baseline
ruled out AMI for 58% of patients, with a negative predictive value of 99%. A total of 72% of
patients with initially normal cTnI subsequently diagnosed with AMI, had elevated copeptin
at presentation. Undetectable copeptin levels may help to identify low-risk patients with chest
pain who can be discharged after a single biomarker assessment.
